Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H24O2 |
| Molecular Weight | 272.382 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1CC[C@@H]2O
InChI
InChIKey=VOXZDWNPVJITMN-ZBRFXRBCSA-N
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
| Molecular Formula | C18H24O2 |
| Molecular Weight | 272.382 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11250930http://www.drugbank.ca/drugs/DB00783https://pubchem.ncbi.nlm.nih.gov/compound/222757Curator's Comment: description was created based on several sources, including
https://books.google.ru/books?id=68n6f1Nw6EEC&pg=PA64&redir_esc=y#v=onepage&q&f=false | https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116143.pdf | https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM338208.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11250930http://www.drugbank.ca/drugs/DB00783https://pubchem.ncbi.nlm.nih.gov/compound/222757
Curator's Comment: description was created based on several sources, including
https://books.google.ru/books?id=68n6f1Nw6EEC&pg=PA64&redir_esc=y#v=onepage&q&f=false | https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm116143.pdf | https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM338208.pdf
Estradiol benzoate is the synthetic benzoate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors. This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. Although estradiol benzoate is not approved by the FDA for use in humans in the United States, it is approved for veterinary use as a subdermal implant both alone (CELERIN®) and in combination with the anabolic steroid trenbolone acetate (SYNOVEX® Plus).
CNS Activity
Sources: https://books.google.ru/books?id=L4YQ50SbBnsC&pg=PA223&lpg=PA223&dq=estradiol+cross+blood+brain+barrier&source=bl&ots=1XAPNkXVXI&sig=_VCp7qIuyiwBe9cGGJDMvmdR8zg&hl=ru&sa=X&ved=0ahUKEwjjk6vD8r7PAhWCFywKHU3xD8c4ChDoAQg4MAU#v=onepage&q=estradiol%20cross%20blood%20brain%20barrier&f=false, retrieved fromhttps://www.ncbi.nlm.nih.gov/pubmed/25231731
Curator's Comment: Known to be CNS active in rats. Human data not available.
Originator
Sources: https://books.google.ru/books?id=_J2ti4EkYpkC&pg=PA1478&lpg=PA1478&dq=ESTRADIOL+year+introduced&source=bl&ots=N5lzH8ALwu&sig=V9zqvrxhsCojxBpoWmAWSN7AXcc&hl=ru&sa=X&ved=0ahUKEwj975678L7PAhVGXSwKHb5cBkUQ6AEISDAH#v=onepage&q=ESTRADIOL%20year%20introduced&f=false, retrieved from Pharmaceutical Manufacturing Encyclopedia, 3rd Edition : William Andrew Publishing, p.1475http://www.google.ru/patents/US2054271
Curator's Comment: Also in Ravina E., Kubinyi H. (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 175.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P08842 Gene ID: 412.0 Gene Symbol: STS Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11250930 |
|||
Target ID: CHEMBL206 Sources: http://www.drugbank.ca/drugs/DB00783 |
0.0084 nM [EC50] | ||
Target ID: CHEMBL242 Sources: http://www.drugbank.ca/drugs/DB00783 |
1.4 nM [EC50] | ||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16309907 |
19.1 nM [IC50] | ||
Target ID: CHEMBL206 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757 |
0.13 nM [Ki] | ||
Target ID: CHEMBL242 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757 |
0.09 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1974 |
|||
| Preventing | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1974 |
|||
| Primary | CLIMARA Approved UseClimara is an estrogen indicated for:
•Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause
•Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause
•Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure
•Prevention of Postmenopausal Osteoporosis Launch Date1974 |
|||
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
92 pg/mL |
0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered: |
ESTRADIOL serum | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
14.7 pg/mL |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL serum | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
236 pg × h/mL |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL serum | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.75 h |
0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered: |
ESTRADIOL serum | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
|
10 h |
0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ESTRADIOL serum | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/abs/10.1021/mp900077q Page: - |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
minor | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
yes [Km 7 uM] | |||
Page: - |
yes | |||
Page: - |
yes | |||
Sources: https://www.pnas.org/content/93/18/9776.short Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Complex actions of estradiol-3-sulfate in late gestation fetal brain. | 2011-07 |
|
| Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. | 2007-03-10 |
|
| Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. | 2001-04-06 |
|
| Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. | 2001-04 |
|
| Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. | 2001-03-23 |
|
| Enhanced multispecificity of arabidopsis vacuolar multidrug resistance-associated protein-type ATP-binding cassette transporter, AtMRP2. | 2001-03-23 |
|
| Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. | 2001-03-02 |
|
| Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERalpha and ERbeta ) at AP-1 sites. | 2001-02-09 |
|
| Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. | 2001-02-02 |
|
| Vitellogenin-induced pathology in male summer flounder (Paralichthys dentatus). | 2001-02 |
|
| Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. | 2001-02 |
|
| Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17beta -iodoacetoxy-estradiol-3-sulfate. | 2001-01-19 |
|
| Effects of heterocyclic amines with mammary gland carcinogenic potential on estrogenic response of uterus in ovariectomized rats. | 2001-01-10 |
|
| Reduction of gamma-aminobutyric acid-ergic neurotransmission as a putative mechanism of radiation induced activation of the gonadotropin releasing-hormone-pulse generator leading to precocious puberty in female rats. | 2001-01-05 |
|
| Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum. | 2001-01-05 |
|
| Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells. | 2001-01-05 |
|
| In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol. | 2001-01-05 |
|
| Effects of follicle-stimulating hormone with and without luteinizing hormone on serum hormone concentrations, follicle growth, and intrafollicular estradiol and aromatase activity in gonadotropin-releasing hormone-immunized heifers. | 2001-01 |
|
| Female steroid hormones modulate receptors for nerve growth factor in rat dorsal root ganglia. | 2001-01 |
|
| Regulation and role of vascular endothelial growth factor in the corpus luteum during mid-pregnancy in rats. | 2001-01 |
|
| Increased expression of a novel heat shock protein transcript in the mouse uterus during decidualization and in response to progesterone. | 2001-01 |
|
| Regulation of progesterone receptors and decidualization in uterine stroma of the estrogen receptor-alpha knockout mouse. | 2001-01 |
|
| Pregnancy stimulates secretion of adrenocorticotropin and nitric oxide from peripheral bovine lymphocytes. | 2001-01 |
|
| Follicle selection in cattle: role of luteinizing hormone. | 2001-01 |
|
| Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. | 2001-01 |
|
| Changes in follicle-stimulating hormone and follicle populations during the ovarian cycle of the common marmoset. | 2001-01 |
|
| Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. | 2001-01 |
|
| Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride. | 2001-01 |
|
| Metabolism of estradiol, ethynylestradiol, and moxestrol in rat uterus, vagina, and aorta: influence of sex steroid treatment. | 2001-01 |
|
| Sex steroid hormones enhance immune function in male and female Siberian hamsters. | 2001-01 |
|
| Rapid and reversible inhibition of brain aromatase activity. | 2001-01 |
|
| Oestrogen-induced changes in the synaptology of the monkey (Cercopithecus aethiops) arcuate nucleus during gonadotropin feedback. | 2001-01 |
|
| Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes. | 2001-01 |
|
| Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. | 2001-01 |
|
| Heat-shock factor-1, steroid hormones, and regulation of heat-shock protein expression in the heart. | 2001-01 |
|
| Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. | 2001-01 |
|
| Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. | 2001-01 |
|
| Evaluation of an EIA method for measuring serum levels of the estrogen metabolite 2-hydroxyestrone in adults. | 2001-01 |
|
| Estradiol levels in psychotic disorders. | 2001-01 |
|
| Neuroprotection by estradiol. | 2001-01 |
|
| Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. | 2000-12 |
|
| Estradiol enhances the resistance of LDL to oxidation by stabilizing apoB-100 conformation. | 2000-11-14 |
|
| Female sex steroids: effects upon microglial cell activation. | 2000-11-01 |
|
| Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. | 2000-11 |
|
| Repression of chick multidrug resistance-associated protein 1 (chMRP1) gene expression by estrogen. | 2000-10-31 |
|
| Relative binding affinity does not predict biological response to xenoestrogens in rat endometrial adenocarcinoma cells. | 2000-10 |
|
| Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. | 2000-10 |
|
| NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1. | 2000-09 |
|
| [The effect of adrenaline and 17beta-estradiol sulfate on transmembrane potentials of guinea pig cardiomyocytes]. | 1996-12 |
|
| Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase. | 1992-05-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Estradiol benzoate is not approved by the FDA for use in humans in the United States.
Unknown
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21273638
Estradiol-3-sulfate (E2SO4) infused intracerebroventricularly (icv) significantly increased plasma adrenocorticotropic hormone (ACTH) and cortisol concentrations. All minipumps in the treated fetuses were filled with E2SO4 in the vehicle (water) and minipumps in the control fetuses were filled with vehicle only. These minipumps deliver a constant infusion of 5 μL/h; the concentration of E2SO4 in infusates was therefore 8.33 μg/μL. It was concluded, that E2SO4 had complex actions on the fetal brain, which might involve deconjugation by steroid sulfatase. But that the net result of direct E2SO4 icv infusion was more complex than could be accounted for by infusion of E2 alone.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:51:25 GMT 2025
by
admin
on
Mon Mar 31 17:51:25 GMT 2025
|
| Record UNII |
4TI98Z838E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
35384-7
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
34290-7
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
34286-5
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
12595-5
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2239-2
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
WHO-ATC |
G03CA03
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
WHO-VATC |
QG03CA03
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
CFR |
21 CFR 522.840
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
83097-6
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2240-0
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
14715-7
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
15062-3
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
12214-3
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
34288-1
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
FDA ORPHAN DRUG |
231706
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
WHO-VATC |
QG03CA53
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
25401-1
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
CFR |
21 CFR 310.527
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
WHO-VATC |
QG03AB08
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
NDF-RT |
N0000011402
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
WHO-ATC |
G03AA14
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
13883-4
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2246-7
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
WHO-VATC |
QG03AA14
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
CFR |
21 CFR 556.240
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
72873-3
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
34287-3
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
55857-7
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
35207-0
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
21263-9
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LIVERTOX |
372
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2243-4
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2245-9
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2238-4
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
31176-1
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
WHO-ATC |
G03CA53
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
WHO-ATC |
G03AB08
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
14960-9
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2241-8
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
IOA (WITHDRAWN: CONTRACEPTION)
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
NDF-RT |
N0000000100
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
12213-5
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
34291-5
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
CFR |
21 CFR 522.2477
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
NDF-RT |
N0000175825
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
44730-0
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
34289-9
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
CFR |
21 CFR 862.1260
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
NCI_THESAURUS |
C2293
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
13736-4
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
55858-5
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
83096-8
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2242-6
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
||
|
LOINC |
2244-2
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1013
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
200-023-8
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
ESTRADIOL
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
Estradiol
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
DB00783
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
SUB96040
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
23965
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
m5028
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
Estradiol (medication)
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
D004958
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
20293
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
DTXSID0020573
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
406
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
C478
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL135
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
1057
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
50-28-2
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
100000091739
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
9895
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
4TI98Z838E
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
16469
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
1250008
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
SUB07242MIG
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
4TI98Z838E
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
4083
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB21195
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
3589
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY | |||
|
5757
Created by
admin on Mon Mar 31 17:51:25 GMT 2025 , Edited by admin on Mon Mar 31 17:51:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
SOLVATE->ANHYDROUS | |||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
LABELED -> NON-LABELED |
|
||
|
|
SUBSTANCE->BASIS OF STRENGTH |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
Binding Assay
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.
|
||
|
METABOLITE -> PARENT |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.
|
||
|
METABOLITE LESS ACTIVE -> PARENT | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT | |||
|
PARENT -> METABOLITE ACTIVE | |||
|
PARENT -> METABOLITE |
Metabolite produced by hydrolysis. Estramustine,s primary mechanism of antineoplastic action is inhibition of mitosis.
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
|
||
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Tmax | PHARMACOKINETIC |
|
ESTRADIOL VALERATE |
|
||
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
ESTRADIOL VALERATE |
|
||